The Nature of Diamino Linker and Halogen Bonding De ﬁ ne Selectivity of Pyrrolopyrimidine - Based LIMK1 Inhibitors Daryl Ariawan 1 , Carol Au 1 , Esmeralda Paric 1 , Thomas Fath 1 , Yazi D . Ke 1 , Michael Kassiou 2 , Janet van Eersel 1 and Lars M . Ittner 1 * 1 Dementia ResearchCentre , Department ofBiomedicalScience , FacultyofMedicine andHealthSciences , MacquarieUniversity , Sydney , NSW , Australia , 2 School of Chemistry , The University of Sydney , Darlington , NSW , Australia The LIM - domain kinase ( LIMK ) family consists of two isoforms , LIMK1 and LIMK2 , which are highly homologous , making selective inhibitor development challenging . LIMK regulates dynamics of the actin cytoskeleton , thereby impacting many cellular functions including cell morphology and motility . Here , we designed and synthesised analogues of a known pyrrolopyrimidine LIMK inhibitor with moderate selectivity for LIMK1 over LIMK2 to gain insights into which features contribute to both activity and selectivity . We incorporated a different stereochemistry around a cyclohexyl central moiety to achieve better selectivity for different LIMK isoforms . Inhibitory activity was assessed by kinase assays , and biological effects in cells were determined using an in vitro wound closure assay . Interestingly , a slight change in stereochemistry alters LIMK isoform selectivity . Finally , a docking study was performed to predict how the new compounds interact with the target . Keywords : LIMK , kinase inhibitor , SAR , co ﬁ lin phosphorylation , actin cytoskeleton INTRODUCTION The LIM - domain kinase ( LIMK ) are a family of serine / threonine protein kinases that act downstream of Rho GTPases . Co ﬁ lin , the known LIMK substrate , is a key regulator on actin skeleton dynamics ( Bernard 2007 ; Scott and Olson 2007 ) . LIMKs phosphorylate co ﬁ lin at the Ser3 position . Once phosphorylated , co ﬁ lin can no longer bind to actin , leading to the accumulation of actin polymers ( Tanaka et al . , 2018 ; Ben Zablah et al . , 2020 ) . Aside from actin cytoskeletal regulation , LIMKs also play an important role in microtubule organisation ( Bernard 2007 ; Scott and Olson 2007 ; Prunier et al . , 2017 ) . The increased activity of the LIMK1 isoform has been associated with several diseases including Alzheimer ’ s diseases ( AD ) ( Heredia et al . , 2006 ; Piccioli and Littleton 2014 ) , cancer ( Davila et al . , 2007 ; Kang et al . , 2021 ; Shi et al . , 2021 ) , and HIV ( Vorster et al . , 2011 ; Wen et al . , 2014 ) . One of the hallmarks of AD is characterised by deposition of the β - amyloid peptide ( A β ) ( Murphy and Levine 2010 ) . A β deposition has a detrimental effect on actin cytoskeleton , and recent studies indicated involvement of the Rho - GTPase pathway ( Rush et al . , 2018 ) . LIMK1 inhibition has shown protection against A β toxicity in primary neurons and mice ( Heredia et al . , 2006 ; Henderson et al . , 2019 ) . Inhibition of LIMK1 also shows bene ﬁ cial effects in cancer . Accordingly , overexpression of LIMK1 in breast cancer cell lines MCF - 7 and MDA - MB - 231 increased their motility , while Edited by : Zhenjun Yang , Peking University , China Reviewed by : Ahmed Elkamhawy , Mansoura University , Egypt Rupesh V . Chikhale , University of Cambridge , United Kingdom * Correspondence : Lars M . Ittner lars . ittner @ mq . edu . au Specialty section : This article was submitted to Medicinal and Pharmaceutical Chemistry , a section of the journal Frontiers in Chemistry Received : 22 September 2021 Accepted : 16 November 2021 Published : 13 December 2021 Citation : Ariawan D , Au C , Paric E , Fath T , Ke YD , Kassiou M , van Eersel J and Ittner LM ( 2021 ) The Nature ofDiamino Linker and Halogen Bonding De ﬁ ne Selectivity of Pyrrolopyrimidine - Based LIMK1 Inhibitors . Front . Chem . 9 : 781213 . doi : 10 . 3389 / fchem . 2021 . 781213 Frontiers in Chemistry | www . frontiersin . org December 2021 | Volume 9 | Article 781213 1 ORIGINAL RESEARCH published : 13 December 2021 doi : 10 . 3389 / fchem . 2021 . 781213 inhibition of LIMK1 attenuated this effect ( Yoshioka et al . , 2003 ) . Targeting LIMK1 in lung cancer cells inhibits cell proliferation and induces apoptosis ( Zhang et al . , 2021 ) . Thus , LIMK1 is a promising drug target , potentially for a range of diseases . Several LIMK1 inhibitors based on the pyrrolopyrimidine scaffold have been reported ( Figure 1 ) ( Harrison et al . , 2009 ; Boland et al . , 2015 ; Yin et al . , 2015 ; Yi et al . , 2017 ) . Compound 1 was reported as part of the development of potent LIMK2 inhibitors ( Harrison et al . , 2009 ) but has a slightly higher activity against LIMK1 . Accordingly , compound 1 was reported to have an IC 50 of 0 . 5 and 0 . 9 nM for inhibiting LIMK1 and LIMK2 , respectively ( Harrison et al . , 2009 ) . In this work , we report modi ﬁ cations of the central piperidine linker motif to explore the effects of conformational ﬂ exibility and halogen exchange of the phenyl cyanoguanidine motif to probe LIMK activity and selectivity ( Figure 1B ) . We tested the FIGURE 1 | ( A ) Structure of known pyrrolopyrimidine LIMK inhibitor and their inhibitor pro ﬁ le . ( B ) Scaffold modi ﬁ cation in this work . SCHEME 1 | General synthetic procedure . Reagents and condition : ( A ) diaminoalkane linker , diisopropylethylamine , isopropanol , re ﬂ ux , 16 h , 50 – 97 % ; ( B ) cyanoguanidine 7 , triethylamine , MeCN , re ﬂ ux , 16 h , 16 % – 39 % . Frontiers in Chemistry | www . frontiersin . org December 2021 | Volume 9 | Article 781213 2 Ariawan et al . LIMK Selective Inhibitors compounds against LIMK1 and LIMK2 to explore the selectivity and their effect on cellular based assay ( Figure 2 ) . RESULTS AND DISCUSSION The approach for investigating different amine linkers is described in Scheme 1 . Brie ﬂ y , the nucleophilic substitution of chloropyrrolopyrimidine ( 5 ) with various diamino alkane linkers afforded the desired amine derivatives ( 6 ) ( Scheme 1 ) . These amines were then converted to target compounds 8 – 19 by reaction with a range of halogen - substituted phenyl cyanocarbamamimidates ( 7 ) , ( Scheme 1 ) ( Harrison et al . , 2009 ) . A structure – activity relationship for compounds 8 – 19 was initially established by measuring inhibition against LIMK1 at a concentration of 0 . 1 μ M for each compound ( Table 1 ) . Substituting the piperidine linker motif in 1 with an ethyl linker ( 9 ) decreased inhibitory activity at LIMK1 by threefold when assayed at 0 . 1 μ M despite the similar distance between the two nitrogens in the linker ( Table 1 ) . Increasing the linker chain to a propyl motif ( 12 ) abolished the inhibitory activity while the longer butyl linker ( 15 ) restored the inhibitory activity to 47 % . Incorporating the conformationally restricted 1 , 4 - diaminocyclohexane linker ( 18 ) increased the inhibitory activity to 69 % . Thus , it can be implied that the ring linker is needed for hydrophobic interaction within the binding pocket . We next turned our attention to the halogen at the phenyl cyanoguanidine motif . Chloride analogues with ethyl and butyl linkers ( 8 and 14 , respectively ) completely abolished inhibitory activity . The propyl linker , chloride analogue 11 , displayed a minimal inhibitory effect of 15 % , while with the 1 , 4 - cyclohexyl linker , the chloride analogue 17 decreased the inhibitory activity compared to the bromide analogue 18 from 69 % to 42 % , respectively . Iodide substitution with the ethyl linker ( 7 ) showed a twofold decrease in inhibitory activity compared to 9 . Using the propyl linker motif , iodide analogue 13 gave a similar inhibitory pro ﬁ le to chloride analogue 11 . For the butyl and cyclohexyl linkers , iodide substitution ( 16 and 19 , respectively ) gave similar potencies to bromide analogues ( 15 and 18 ) . Given the LIMK1 inhibition of the cyclohexyl analogues 17 – 19 , we next investigated the amino 1 , 2 - diaminocyclohexyl analogues 23 – 26 ( Table 2 ) . We were furthermore interested to see the effects of changing bromide to iodide in the lead compound 1 . Compound 22 , the iodide analogue of 1 , was synthesised in a similar fashion ( Scheme 2 ) . FIGURE 2 | Work ﬂ ow of this study . SCHEME 2 | Synthesis of iodide analogues of compound 1 . Reagents and condition : ( A ) ( S ) - tert - butyl 2 - methylpiperazine - 1 - carboxylate , diisopropylethylamine , isopropanol , re ﬂ ux , 16 h ; ( B ) 50 % TFA in DCM , rt , 3 h , 90 % over two steps ; ( C ) cyanoguanidine 21 , triethylamine , MeCN , re ﬂ ux , 16 h , 8 % . Frontiers in Chemistry | www . frontiersin . org December 2021 | Volume 9 | Article 781213 3 Ariawan et al . LIMK Selective Inhibitors FIGURE 3 | Delayed wound closure in scratch assays upon LIMK inhibition . ( A ) Representative scratch assay images at 0 and 12 h for compounds 1 and 22 – 26 . Yellow lines indicate the edges of the scratch wound and therefore starting point of cell migration . ( B ) Quanti ﬁ cation of cell velocity from six independent experiments using single - cell tracing . Frontiers in Chemistry | www . frontiersin . org December 2021 | Volume 9 | Article 781213 4 Ariawan et al . LIMK Selective Inhibitors FIGURE 4 | Predicted binding poses of ligand 1 ( A ) , 24 ( B ) , and 26 ( C ) into the ATP - binding pocket of LIMK1 . FIGURE 5 | Predicted binding poses of ligand 1 ( A ) , 24 ( B ) , and 26 ( C ) into the ATP - binding pocket of LIMK2 . Frontiers in Chemistry | www . frontiersin . org December 2021 | Volume 9 | Article 781213 5 Ariawan et al . LIMK Selective Inhibitors Our in - house measurement of LIMK1 inhibition resulted in > 90 % inhibition at 0 . 1 μ M for all the 1 , 2 - diaminocyclohexyl analogues ( 23 – 26 ) ( Table 2 ) . Similar results were also achieved with the lead compound ( 1 ) and its iodide analogue ( 22 ) . Given this high potency toward LIMK1 , we next investigated the selectivity pro ﬁ le of these compounds . LIMK1 and LIMK2 exhibit the same domain architecture and have overlapping substrate speci ﬁ cities . While targeting LIMK1 has been used in vivo in cancer ( Zhang et al . , 2021 ) and AD mouse models ( Henderson et al . , 2019 ) , LIMK2 functionality is essential for proper functionality of the eye ( Rice et al . , 2012 ) and in spermatogenesis ( Takahashi et al . , 2002 ) . Thus , a speci ﬁ c LIMK1 isoform inhibition is desirable . To measure the selectivity against LIMK isoforms , the radiotracer assay measuring the transfer of 33 P from ATP to the substrate was used since there was no ADP - Glo ™ kinase assay system available for LIMK2 ( Table 2 ) . Substitution of bromide in compound 1 to iodide in compound 22 resulted in a twofold potency increase for both LIMK1 and LIMK2 . Compounds 23 – 26 were signi ﬁ cantly less potent than compounds 1 and 22 . Interestingly , however , the stereochemistry of the cyclohexyl linker changed the inhibitory bias toward LIMK1 over LIMK2 . Compounds 25 and 26 bearing the ( R , R ) - 1 , 2 - cyclohexyl linker were selective toward LIMK1 , with no signi ﬁ cant inhibition of LIMK2 . For comparison , compounds 23 and 24 bearing the ( S , S ) - 1 , 2 - cyclohexyl linker had a slightly higher potency toward LIMK2 than LIMK1 . Scratch Assay Co ﬁ lin , the substrate for LIMK1 , regulates the actin skeleton and thus regulates cell migration ( Bravo - Cordero et al . , 2013 ) . To understand the inhibitory effect of compounds 1 and 22 – 26 in vitro , scratch assays were performed . The arti ﬁ cial wound was created by “ scratching ” in the middle of the well with con ﬂ uent C6 cells in culture . Live imaging was captured for 24 h to measure the distance of cell migration ( Figure 3 ; Supplementary video ) . All compounds tested in the scratch assay showed signi ﬁ cant reduction in cell migration velocity . Among the cyclohexyl analogues 23 – 26 , there is no signi ﬁ cant difference in the cell velocity . The lead compound 1 reduced the cell velocity by twofold compared to the untreated cell . Substitution from TABLE 1 | Synthesis of initial investigation of linker chain and halide substitutions . Compound Amine linker X = % LIMK1 inhibition at 0 . 1 μ M a 1 Br 94 . 3 ± 0 . 2 8 Cl - b 9 Br 29 . 4 ± 10 . 3 10 I 17 . 8 ± 7 . 1 11 Cl 15 . 0 ± 10 . 7 12 Br - b 13 I 17 . 8 ± 7 . 1 14 Cl - b 15 Br 47 . 1 ± 1 . 6 16 I 41 . 0 ± 2 . 5 17 Cl 41 . 7 ± 0 . 1 18 Br 69 . 2 ± 1 . 7 ( Continued in next column ) TABLE 1 | ( Continued ) Synthesis of initial investigation of linker chain and halide substitutions . Compound Amine linker X = % LIMK1 inhibition at 0 . 1 μ M a 19 I 66 . 6 ± 8 . 8 a Measured in Promega ADP - Glo ™ kinase Assay system . b No inhibition at 0 . 1 uM . Frontiers in Chemistry | www . frontiersin . org December 2021 | Volume 9 | Article 781213 6 Ariawan et al . LIMK Selective Inhibitors bromide to iodide in compound 22 lowered the migration even further . Overall , the cell migration velocity re ﬂ ects the IC 50 value measured by the radiotracer assay ( Reaction Biology Corporation ) . Thus , it can be implied that these inhibitors work by hindering the binding of ATP into LIMK . Docking Study Docking studies were performed for piperazine and cyclohexyl analogues to rationalise the selectivity trends against LIMK1 and LIMK2 . A published crystal structure of LIMK1 ( PDB : 5NXC ) ( Mathea et al . , 2017 ) and LIMK2 ( PDB : 4TPT ) ( Goodwin et al . , 2015 ) bound with inhibitor formed the basis for our docking study , which we performed using Schrodinger GLIDE . Re - docking the ligand from the crystal structure generated a binding pose with RMSD < 2 . 0 Å , providing con ﬁ dence that the docking protocol is reliable ( Supplementary Figures S1 , S2 ) . The predicted binding pose of 1 to LIMK1 is shown in Figure 4 . The key interaction of compound 1 includes hydrogen bonding of pyrrolopyrimidine moiety to Ile 416 and hydrogen bonding of cyanoguanidine moiety to Asp 478 of LIMK1 . Hydrogen bonding with Ile 416 is detrimental for this potency as shown by previous structure – activity studies ( Cui et al . , 2015 ; Yin et al . , 2015 ) . It is important to note that the hydrophobic interaction around piperazine and aryl moieties also contributes to high potency of compound 1 . Incorporation of the 1 , 2 - diamino cyclohexyl motif changed the 3D structure of the ligand and thus changed the binding pose into the ATP - binding pocket of LIMK1 . Docking of ligand 24 resulted in a binding pose with the iodophenyl moiety facing toward the inside of the binding pocket . Compound 26 maintained the hydrogen bonding of the cyanoguanidine moiety to Asp 478 while losing the hydrogen bonding to Ile 416 due to the rigidity of the cyclohexyl group . The absence of hydrogen bonding into Ile 416 could be the reason for the reduction in potency . The predicted binding pose toward LIMK2 is shown in Figure 5 . Lead compound 1 formed a hydrogen bond between the cyanoguanidine moiety with Phe 470 of LIMK2 . Although it only formed 1 hydrogen bond , the hydrophobic interaction with the surface residue could be accounted for its high potency . Compound 24 also formed hydrogen bonding with Phe 470 , but the cyclohexyl moiety is directed differently compared to piperazine moiety in compound 1 . Due to this orientation , the hydrophobic interaction within the middle binding tunnel is different , which accounts for the different potency . Compound 26 bearing the ( R , R ) - cyclohexyl motif resulted in a binding pose with the iodophenyl moiety facing toward the inside of the binding pocket . This could be the reason for the lower inhibitory effect of 26 toward LIMK2 . Overall , changing the stereochemistry of the cyclohexyl group resulted in the switch of the binding pose . The orientation of the pyrrolopyrimidine moiety was detrimental to selectivity . When the pyrrolopyrimidine was oriented into the interior of one of the LIMK isoforms while facing outside on the other isoform , a binding selectivity was achieved . CONCLUSION A series of new LIMK inhibitors have been synthesised based on lead compound 1 , in which the central linker portion is designed with a certain degree of ﬂ exibility . We identify the TABLE 2 | Inhibition pro ﬁ le of diaminocyclohexyl linker analogues . Compound X = % LIMK1 inhibition at 0 . 1 μ M a IC 50 ( nM ) b LIMK1 LIMK2 1 Br 94 . 3 ± 0 . 2 0 . 28 ± 0 . 01 0 . 86 ± 0 . 05 22 I 95 . 5 ± 0 . 4 0 . 13 ± 0 . 01 0 . 47 ± 0 . 01 23 Br 96 . 7 ± 0 . 1 2 , 830 ± 37 2 , 651 ± 15 24 I 93 . 2 ± 1 . 2 5 , 083 ± 14 3 , 380 ± 19 25 Br 96 . 0 ± 0 . 5 47 % c > 10 μ M 26 I 94 . 9 ± 0 . 8 8 , 360 ± 21 > 10 μ M a Measured in Promega ADP - Glo ™ kinase Assay system . b Measured on the transfer of 33 P - labelled phosphate from ATP , to the kinase substrate ( co ﬁ lin ) by Reaction Biology Corporation . c Inhibition at 10 μ M . Frontiers in Chemistry | www . frontiersin . org December 2021 | Volume 9 | Article 781213 7 Ariawan et al . LIMK Selective Inhibitors stereochemistry of 1 , 2 - diaminocyclohexyl moiety as detrimental to LIMK isoform selectivity . The docking study revealed that these subtle stereochemistry differences alter the binding pose which reform the ligand - binding site interaction . We also investigated the effect of halogen substitution . We found that substitution of bromide to iodide in compound 22 improved the potency of lead compound 1 . Taken together , the selectivity achieved in this work will be valuable in aiding the development of more potent yet selective LIMK inhibitors for future studies . MATERIALS AND METHODS Chemistry All chemicals were purchased from a commercial source and used without any further puri ﬁ cation . All HPLC puri ﬁ cations were performed in Shimadzu LC - 20 AD equipped with a fraction collector . 1 H - NMR and 13 C - NMR were recorded on Bruker AVIIIHD 400 and 500 MHz . All melting points were measured in Stuart Digital SMP10 . Mass spectrometry was measured on Shimadzu LC - MS 8050 . General synthetic procedure A : the mixture of pyrrolopyrimidine ( 1 mmol ) , diamino alkane ( 5 mmol ) , and DIPEA ( 3 mmol ) in isopropanol ( 10 ml ) was stirred at re ﬂ ux overnight . Water was added to the reaction mixture , and the mixture was lyophilised . The crude product was puri ﬁ ed with semi - preparative HPLC using the gradient of acetonitrile / water with 0 . 1 % formic acid . General synthetic procedure B : the mixture of 3 - haloanoline ( 1 mmol ) and diphenyl - N - cyanocarbonimidate ( 1 mmol ) in acetonitrile ( 15 ml ) was heated at 50 ° C overnight . The mixture was then cooled in ice bath , resulting in precipitation of the product . The crystalline solid was collected by ﬁ ltration . The product was used for the next step without any further puri ﬁ cation . General synthetic procedure C : the amino or piperazine substituted pyrrolopyrimidine ( 1 mmol ) , phenyl carbaimidates ( 2 mmol ) , and Et 3 N ( 3 mmol ) in acetonitrile ( 7 ml ) and methanol ( 3 ml ) was stirred at re ﬂ ux overnight . Water was added to the reaction mixture , and the mixture was lyophilised . The crude product was puri ﬁ ed with semi - preparative HPLC using gradient of acetonitrile / water with 0 . 1 % formic acid . ( S ) - Methyl piperazine 20 : the mixture of pyrrolopyrimidine 5 ( 1 . 2 mmol ) , ( S ) - tert - butyl 2 - methylpiperazine - 1 - carboxylate ( 3 . 6 mmol ) , and DIPEA ( 3 . 6 mmol ) in isopropanol ( 10 ml ) was stirred at re ﬂ ux overnight . The mixture was concentrated under vacuum . The residue was dissolved in 50 % TFA in dichloromethane ( 10 ml ) and stirred overnight at rt . The reaction was concentrated under vacuum , diluted with dichloromethane , and neutralised with sat . aq . sodium bicarbonate . The layers were separated , and the aqueous layer was back extracted with more dichloromethane . The combined organic layers were dried over MgSO 4 and concentrated under vacuum . The crude product was puri ﬁ ed with semi - preparative HPLC using the gradient of acetonitrile / water with 0 . 1 % formic acid . 1 - ( 3 - Chlorophenyl ) - 2 - cyano - 3 - ( 2 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) ethyl ) guanidine ( 8 ) . Total yield : 31 % . Purity : > 99 % . mp : 87 – 88 ° C . 1 H NMR ( DMSO - d 6 , 400 MHz ) : δ 11 . 2 ( s , 1H ) , 9 . 2 ( s , 1H ) , 7 . 98 – 7 . 82 ( m , 2H ) , 7 . 36 – 7 . 23 ( m , 2H ) , 7 . 21 – 7 . 10 ( m , 2H ) , 6 . 77 ( m , 1H ) , 6 . 65 ( m , 1H ) , 3 . 59 ( m , 2H ) , 3 . 40 ( m , 2H ) , 2 . 30 ( d , J (cid:1) 1 . 1 Hz , 3H ) ; 13 C NMR ( DMSO - d 6 , 100 MHz ) : δ 163 . 5 , 158 . 7 , 157 . 1 , 150 . 9 , 139 . 9 , 133 . 4 , 130 . 8 , 124 . 8 , 123 . 6 , 122 . 4 , 119 . 4 , 117 . 6 , 109 . 0 , 102 . 8 , 42 . 6 , 12 . 7 ; ESI - MS : [ M + H ] calc . 369 . 13 , found 369 . 30 . HR - MS ( ESI + ) : [ M + H ] calc . 369 . 1343 , found 369 . 1335 . 1 - ( 3 - Bromophenyl ) - 2 - cyano - 3 - ( 2 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) ethyl ) guanidine ( 9 ) . Total yield : 20 % . Purity : > 99 % . mp : 86 – 88 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 9 . 36 ( s , 1H ) , 8 . 08 ( s , 1H ) , 7 . 39 ( m , 1H ) , 7 . 31 ( d , J (cid:1) 7 . 8 Hz , 1H ) , 7 . 28 ( m , 1H ) , 7 . 23 – 7 . 19 ( m , 2H ) , 7 . 15 – 7 . 00 ( m , 3H ) , 3 . 69 ( t , J (cid:1) 5 . 1 Hz , 2H ) , 3 . 55 ( dd , J (cid:1) 6 . 1 , 4 . 4 Hz , 2H ) , 2 . 40 ( d , J (cid:1) 1 . 1 Hz , 3H ) ; 13 C NMR ( MeOD , 125 MHz ) : δ 164 . 4 , 159 . 2 , 131 . 7 , 130 . 6 , 130 . 5 , 130 . 1 , 129 . 8 , 129 . 0 , 127 . 6 , 127 . 5 , 123 . 3 , 120 . 5 , 114 . 8 , 113 . 5 , 41 . 0 , 41 . 0 , 10 . 7 ; ESI - MS : [ M + H ] calc . 413 . 08 , found 413 . 30 . HR - MS ( ESI + ) : [ M + H ] calc . 413 . 0838 , found 413 . 0827 . 2 - Cyano - 1 - ( 3 - iodophenyl ) - 3 - ( 2 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) ethyl ) guanidine ( 10 ) . Total yield : 5 % . Purity : > 99 % . mp : 88 – 89 ° C 1 H NMR ( MeOD , 400 MHz ) : δ 9 . 35 ( s , 1H ) , 8 . 05 ( s , 1H ) , 7 . 80 ( t , J (cid:1) 1 . 9 Hz , 1H ) , 7 . 61 – 7 . 56 ( m , 2H ) , 7 . 48 – 7 . 37 ( m , 3H ) , 7 . 05 – 6 . 99 ( m , 2H ) , 3 . 67 ( t , J (cid:1) 6 . 0 Hz , 2H ) , 3 . 53 ( dd , J (cid:1) 4 . 1 , 5 . 7 Hz , 2H ) , 2 . 39 ( d , J (cid:1) 1 . 1 Hz , 3H ) ; 13 C NMR ( MeOD , 125 MHz ) : δ 164 . 4 , 162 . 9 , 159 . 2 , 137 . 5 , 136 . 6 , 132 . 5 , 130 . 6 , 130 . 1 , 129 . 9 , 128 . 1 , 123 . 7 , 118 . 6 , 114 . 3 , 92 . 4 , 46 . 6 , 41 . 1 , 10 . 7 ; ESI - MS : [ M + H ] calc . 461 . 06 , found 461 . 25 . HR - MS ( ESI + ) : [ M + H ] calc . 461 . 0699 , found 461 . 0689 . 1 - ( 3 - Chlorophenyl ) - 2 - cyano - 3 - ( 3 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) propyl ) guanidine ( 11 ) . Total yield : 7 % . Purity : > 99 % . mp : 88 – 90 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 7 . 68 ( s , 1H ) , 7 . 32 – 7 . 25 ( m , 2H ) , 7 . 20 – 7 . 11 ( m , 2H ) , 6 . 70 ( d , J (cid:1) 1 . 1 Hz , 1H ) , 3 . 53 ( t , J (cid:1) 6 . 2 Hz , 2H ) , 3 . 29 ( t , J (cid:1) 6 . 4 Hz , 2H ) , 2 . 35 ( d , J (cid:1) 1 . 1 Hz , 3H ) , 1 . 80 – 1 . 72 ( m , 2H ) ; 13 C NMR ( MeOD , 100 MHz ) : δ 158 . 8 , 150 . 1 , 138 . 4 , 134 . 5 , 130 . 4 , 129 . 0 , 125 . 9 , 124 . 7 , 122 . 9 , 118 . 8 , 117 . 5 , 114 . 8 , 109 . 8 , 102 . 5 , 38 . 3 , 37 . 0 , 29 . 5 , 10 . 9 ; ESI - MS : [ M + H ] calc . 383 . 14 , found 383 . 25 . HR - MS ( ESI + ) : [ M + H ] calc . 383 . 1499 , found 383 . 1492 . 1 - ( 3 - Bromophenyl ) - 2 - cyano - 3 - ( 3 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) propyl ) guanidine 12 ) . Total yield : 30 % . Purity : > 99 % . mp : 88 – 89 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 7 . 67 ( s , 1H ) , 7 . 43 ( m , 1H ) , 7 . 32 ( m , 1H ) , 7 . 26 – 7 . 17 ( m , 2H ) , 7 . 08 – 7 . 02 ( m , 1H ) , 6 . 73 – 6 . 63 ( m , 2H ) , 3 . 53 ( t , J (cid:1) 6 . 5 Hz , 2H ) , 3 . 29 ( t , J (cid:1) 6 . 5 Hz , 2H ) , 2 . 35 ( d , J (cid:1) 1 . 1 Hz , 3H ) , 1 . 76 ( m , 2H ) ; 13 C NMR ( MeOD , 100 MHz ) : δ 158 . 8 , 157 . 2 , 150 . 0 , 149 . 1 , 138 . 5 , 130 . 6 , 128 . 9 , 127 . 6 , 123 . 4 , 118 . 9 , 114 . 8 , 109 . 8 , 102 . 5 , 38 . 3 , 36 . 7 , 29 . 5 , 10 . 8 ; ESI - MS : [ M + H ] calc . 427 . 09 , found 427 . 25 . HR - MS ( ESI + ) : [ M + H ] calc . 427 . 0994 , found 427 . 0986 . 2 - Cyano - 1 - ( 3 - iodophenyl ) - 3 - ( 3 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) propyl ) guanidine ( 13 ) . Total yield : 17 % . Purity : > 99 % . mp : 91 – 93 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 7 . 62 ( t , J (cid:1) 1 . 8 Hz , 2H ) , 7 . 52 ( d , J (cid:1) 7 . 9 Hz , 1H ) , 7 . 23 ( m , 1H ) , 7 . 09 – 7 . 02 ( m , 2H ) , 6 . 71 – 6 . 64 ( m , 2H ) , 3 . 53 ( t , J (cid:1) 6 . 4 Hz , 2H ) , 3 . 28 ( t , J (cid:1) 6 . 4 Hz , 2H ) , 2 . 35 ( d , J (cid:1) 1 . 1 Hz , 3H ) , 1 . 75 ( m , 2H ) ; 13 C NMR ( MeOD , 100 MHz ) : δ 158 . 8 , 157 . 3 , 150 . 1 , 149 . 1 , 138 . 3 , 135 . 0 , 130 . 7 , 129 . 0 , 124 . 1 , 118 . 8 , 117 . 5 , 114 . 8 , 109 . 8 , 102 . 5 , 38 . 2 , 37 . 0 , 29 . 6 , 10 . 9 ; ESI - MS : [ M + H ] calc . 475 . 07 , found 475 . 30 . HR - MS ( ESI + ) : [ M + H ] calc . 475 . 0856 , found 475 . 0847 . Frontiers in Chemistry | www . frontiersin . org December 2021 | Volume 9 | Article 781213 8 Ariawan et al . LIMK Selective Inhibitors 1 - ( 3 - Chlorophenyl ) - 2 - cyano - 3 - ( 4 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) butyl ) guanidine ( 14 ) . Total yield : 55 % . Purity : > 99 % . mp : 90 – 91 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 7 . 94 ( s , 1H ) , 7 . 21 ( t , J (cid:1) 8 . 1 Hz , 1H ) , 7 . 19 ( d , J (cid:1) 2 . 1 Hz , 1H ) , 7 . 10 ( m , 1H ) , 7 . 08 – 7 . 02 ( m , 2H ) , 6 . 71 ( d , J (cid:1) 1 . 1 Hz , 1H ) , 6 . 67 ( m , 1H ) , 3 . 48 ( t , J (cid:1) 6 . 4 Hz , 2H ) , 3 . 25 ( t , J (cid:1) 6 . 4 Hz , 2H ) , 2 . 33 ( d , J (cid:1) 1 . 1 Hz , 3H ) , 1 . 68 – 1 . 54 ( m , 4H ) ; 13 C NMR ( MeOD , 100 MHz ) : δ 158 . 6 , 156 . 9 , 150 . 0 , 138 . 6 , 134 . 3 , 130 . 2 , 128 . 9 , 125 . 4 , 124 . 1 , 122 . 3 , 118 . 9 , 114 . 8 , 109 . 8 , 102 . 6 , 41 . 3 , 40 . 0 , 26 . 5 , 26 . 3 , 10 . 8 ; ESI - MS : [ M + H ] calc . 397 . 16 , found 397 . 25 . HR - MS ( ESI + ) : [ M + H ] calc . 397 . 1656 , found 397 . 1650 . 1 - ( 3 - Bromophenyl ) - 2 - cyano - 3 - ( 4 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) butyl ) guanidine ( 15 ) . Total yield : 47 % . Purity : > 99 % . mp : 97 – 98 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 7 . 94 ( s , 1H ) , 7 . 35 ( t , J (cid:1) 1 . 8 Hz , 1H ) , 7 . 25 ( m , 1H ) , 7 . 15 ( t , J (cid:1) 8 . 0 Hz , 1H ) , 7 . 10 ( m , 1H ) , 7 . 05 ( m , 1H ) , 6 . 72 – 6 . 63 ( m , 2H ) , 3 . 48 ( t , J (cid:1) 6 . 9 Hz , 2H ) , 3 . 25 ( t , J (cid:1) 6 . 9 Hz , 2H ) , 2 . 33 ( d , J (cid:1) 1 . 1 Hz , 3H ) , 1 . 67 – 1 . 55 ( m , 4H ) ; 13 C NMR ( MeOD , 100 MHz ) : δ 158 . 6 , 156 . 9 , 149 . 9 , 149 . 1 , 138 . 7 , 130 . 4 , 129 . 0 , 128 . 4 , 127 . 0 , 122 . 8 , 118 . 9 , 114 . 8 , 109 . 8 , 102 . 6 , 41 . 3 , 40 . 0 , 26 . 5 , 26 . 3 , 10 . 8 ; ESI - MS : [ M + H ] calc . 441 . 11 , found 441 . 30 . HR - MS ( ESI + ) : [ M + H ] calc . 441 . 1151 , found 441 . 1141 . 2 - Cyano - 1 - ( 3 - iodophenyl ) - 3 - ( 4 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) butyl ) guanidine ( 16 ) . Total yield : 53 % . Purity : > 99 % . mp : 90 – 91 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 7 . 94 ( s , 1H ) , 7 . 53 ( t , J (cid:1) 1 . 7 Hz , 1H ) , 7 . 45 ( m , 1H ) , 7 . 13 ( m , 1H ) , 7 . 08 – 6 . 97 ( m , 2H ) , 6 . 72 – 6 . 64 ( m , 2H ) , 3 . 48 ( t , J (cid:1) 6 . 7 Hz , 2H ) , 3 . 24 ( t , J (cid:1) 6 . 9 Hz , 2H ) , 2 . 33 ( d , J (cid:1) 1 . 2 Hz , 3H ) , 1 . 67 – 1 . 54 ( m , 4H ) ; 13 C NMR ( MeOD , 125 MHz ) : δ 158 . 6 , 156 . 9 , 149 . 9 , 138 . 4 , 134 . 6 , 133 . 0 , 130 . 5 , 129 . 0 , 123 . 5 , 118 . 9 , 117 . 5 , 114 . 8 , 109 . 9 , 102 . 6 , 41 . 3 , 40 . 0 , 26 . 5 , 26 . 3 , 10 . 8 ; ESI - MS : [ M + H ] calc . 489 . 09 , found 489 . 30 . HR - MS ( ESI + ) : [ M + H ] calc . 489 . 1012 , found 489 . 1002 . 1 - ( 3 - Chlorophenyl ) - 2 - cyano - 3 - ( ( 1 r , 4 r ) - 4 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) cyclohexyl ) guanidine ( 17 ) . Total yield : 3 % . Purity : > 99 % . mp : 120 – 122 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 7 . 94 ( s , 1H ) , 7 . 29 – 7 . 19 ( m , 2H ) , 7 . 14 – 7 . 06 ( m , 2H ) , 6 . 71 ( d , J (cid:1) 1 . 2 Hz , 1H ) , 3 . 95 ( m , 1H ) , 3 . 74 ( m , 1H ) , 2 . 33 ( d , J (cid:1) 1 . 1 Hz , 3H ) , 2 . 09 – 1 . 93 ( m , 4H ) , 1 . 50 – 1 . 37 ( m , 4H ) ; 13 C NMR ( MeOD , 125 MHz ) : δ 157 . 7 , 156 . 6 , 150 . 4 , 149 . 5 , 138 . 9 , 134 . 4 , 130 . 2 , 125 . 1 , 123 . 4 , 121 . 7 , 118 . 9 , 117 . 3 , 109 . 5 , 102 . 7 , 50 . 7 , 48 . 6 , 31 . 0 , 30 . 8 , 10 . 7 ; ESI - MS : [ M + H ] calc . 423 . 17 , found 423 . 35 . HR - MS ( ESI + ) : [ M + H ] calc . 423 . 1812 , found 423 . 1805 . 1 - ( 3 - Bromophenyl ) - 2 - cyano - 3 - ( ( 1 r , 4 r ) - 4 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) cyclohexyl ) guanidine ( 18 ) . Total yield : 16 % . Purity : > 99 % . mp : 127 – 128 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 7 . 94 ( s , 1H ) , 7 . 36 ( t , J (cid:1) 1 . 9 Hz , 1H ) , 7 . 26 ( m , 1H ) , 7 . 19 ( t , J (cid:1) 8 . 0 Hz , 1H ) , 7 . 13 ( m , 1H ) , 6 . 72 ( d , J (cid:1) 1 . 2 Hz , 1H ) , 3 . 94 ( m , 1H ) , 3 . 73 ( m , 1H ) , 2 . 33 ( d , J (cid:1) 1 . 1 Hz , 3H ) , 2 . 09 – 1 . 92 ( m , 4H ) , 1 . 51 – 1 . 37 ( m , 4H ) ; 13 C NMR ( MeOD , 100 MHz ) : δ 157 . 7 , 156 . 5 , 150 . 2 , 149 . 4 , 139 . 0 , 130 . 4 , 128 . 0 , 126 . 3 , 122 . 1 , 122 . 1 , 119 . 0 , 117 . 3 , 109 . 6 , 102 . 6 , 50 . 7 , 48 . 7 , 31 . 0 , 30 . 8 , 10 . 7 ; ESI - MS : [ M + H ] calc . 467 . 12 , found 467 . 30 . HR - MS ( ESI + ) : [ M + H ] calc . 467 . 1307 , found 467 . 1297 . 2 - Cyano - 1 - ( 3 - iodophenyl ) - 3 - ( ( 1 r , 4 r ) - 4 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) cyclohexyl ) guanidine ( 19 ) . Total yield : 11 % . Purity : > 99 % . mp : 129 – 130 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 9 . 36 ( s , 1H ) , 8 . 02 ( s , 1H ) , 7 . 59 ( dt , J (cid:1) 7 . 5 , 1 . 5 Hz , 1H ) , 7 . 54 ( t , J (cid:1) 1 . 8 Hz , 1H ) , 7 . 46 ( m , 1H ) , 7 . 38 ( t , J (cid:1) 2 . 0 Hz , 1H ) , 7 . 16 ( m , 1H ) , 7 . 07 – 7 . 01 ( m , 2H ) , 2 . 37 ( d , J (cid:1) 1 . 1 Hz , 3H ) , 2 . 02 ( m , 4H ) , 1 . 64 – 1 . 36 ( m , 4H ) ; 13 C NMR ( MeOD , 125 MHz ) : δ 164 . 4 , 157 . 7 , 137 . 5 , 136 . 5 , 134 . 3 , 132 . 4 , 130 . 5 , 129 . 9 , 128 . 1 , 122 . 8 , 120 . 0 , 117 . 3 , 114 . 0 , 93 . 4 , 50 . 5 , 49 . 4 , 30 . 7 , 30 . 7 , 10 . 6 ; ESI - MS : [ M + H ] calc . 515 . 11 , found 515 . 30 . HR - MS ( ESI + ) : [ M + H ] calc . 515 . 1169 , found 515 . 1159 . ( S ) - N 9 - Cyano - N - ( 3 - iodophenyl ) - 2 - methyl - 4 - ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) piperazine - 1 - carboximidamide ( 22 ) . Total yield : 7 % . Purity : > 99 % . mp : 130 – 131 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 8 . 13 ( s , 1H ) , 7 . 43 – 7 . 36 ( m , 2H ) , 7 . 07 – 6 . 92 ( m , 3H ) , 4 . 52 ( m , 1H ) , 4 . 06 ( m , 1H ) , 3 . 90 ( m , 1H ) , 3 . 83 ( m , 1H ) , 3 . 59 ( m , 1H ) , 3 . 39 ( dd , J (cid:1) 13 . 1 , 3 . 9 Hz , 1H ) , 3 . 09 ( m , 1H ) , 2 . 36 ( d , J (cid:1) 1 . 1 Hz , 3H ) , 1 . 24 ( d , J (cid:1) 6 . 8 Hz , 3H ) ; 13 C NMR ( MeOD , 125 MHz ) : δ 161 . 2 , 158 . 4 , 152 . 1 , 149 . 4 , 140 . 0 , 133 . 1 , 130 . 5 , 130 . 1 , 121 . 6 , 120 . 5 , 116 . 1 , 109 . 1 , 106 . 6 , 93 . 4 , 52 . 1 , 50 . 8 , 49 . 6 , 41 . 4 , 15 . 0 , 12 . 5 ; ESI - MS : [ M + H ] calc . 501 . 09 , found 501 . 20 . HR - MS ( ESI + ) : [ M + H ] calc . 501 . 1012 , found 501 . 1003 . 1 - ( 3 - Bromophenyl ) - 2 - cyano - 3 - ( ( 1 R , 2 R ) - 2 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) cyclohexyl ) guanidine ( 23 ) . Total yield : 8 % . Purity : > 99 % . mp : 127 – 128 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 7 . 73 ( s , 1H ) , 7 . 21 ( m , 1H ) , 7 . 05 ( t , J (cid:1) 1 . 9 Hz , 1H ) , 7 . 00 ( t , J (cid:1) 8 . 0 Hz , 1H ) , 6 . 79 ( m , 1H ) , 6 . 73 ( d , J (cid:1) 1 . 2 Hz , 1H ) , 4 . 05 ( m , 1H ) , 3 . 84 ( m , 1H ) , 2 . 37 ( d , J (cid:1) 1 . 2 Hz , 3H ) , 2 . 03 ( m , 2H ) , 1 . 72 ( m , 2H ) , 1 . 49 – 1 . 28 ( m , 4H ) ; 13 C NMR ( MeOD , 100 MHz ) : δ 158 . 5 , 157 . 2 , 150 . 4 , 138 . 4 , 136 . 2 , 130 . 4 , 128 . 6 , 126 . 9 , 122 . 6 , 122 . 2 , 119 . 1 , 117 . 2 , 109 . 6 , 102 . 6 , 56 . 3 , 53 . 7 , 32 . 1 , 31 . 6 , 24 . 5 , 24 . 4 , 10 . 9 ; ESI - MS : [ M + H ] calc . 467 . 12 , found 467 . 30 . HR - MS ( ESI + ) : [ M + H ] calc . 467 . 1307 , found 467 . 1297 . 2 - Cyano - 1 - ( 3 - iodophenyl ) - 3 - ( ( 1 R , 2 R ) - 2 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) cyclohexyl ) guanidine ( 24 ) . Total yield : 9 % . Purity : > 99 % . mp : 128 – 129 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 7 . 85 ( s , 1H ) , 7 . 42 ( td , J (cid:1) 7 . 0 , 1 . 8 Hz , 1H ) , 7 . 26 ( m , 1H ) , 6 . 90 – 6 . 81 ( m , 3H ) , 3 . 99 ( m , 1H ) , 3 . 89 ( m , 1H ) , 2 . 39 ( d , J (cid:1) 1 . 2 Hz , 2H ) , 2 . 03 ( m , 2H ) , 1 . 72 ( m , 2H ) , 1 . 52 – 1 . 28 ( m , 4H ) ; 13 C NMR ( MeOD , 125 MHz ) : δ 158 . 5 , 147 . 9 , 138 . 1 , 134 . 8 , 132 . 9 , 130 . 5 , 132 . 3 , 120 . 0 , 117 . 0 , 110 . 5 , 102 . 4 , 93 . 5 , 55 . 7 , 54 . 6 , 31 . 8 , 31 . 5 , 24 . 4 , 24 . 3 , 10 . 8 ; ESI - MS : [ M + H ] calc . 515 . 11 , found 515 . 20 . HR - MS ( ESI + ) : [ M + H ] calc . 515 . 1169 , found 515 . 1157 . 1 - ( 3 - Bromophenyl ) - 2 - cyano - 3 - ( ( 1 S , 2 S ) - 2 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) cyclohexyl ) guanidine ( 25 ) . Total yield : 7 % . Purity : > 99 % . mp : 127 – 128 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 7 . 72 ( s , 1H ) , 7 . 21 ( m , 1H ) , 7 . 05 ( t , J (cid:1) 1 . 9 Hz , 1H ) , 7 . 00 ( t , J (cid:1) 8 . 0 Hz , 1H ) , 6 . 79 ( m , 1H ) , 6 . 73 ( d , J (cid:1) 1 . 2 Hz , 1H ) , 4 . 04 ( m , 1H ) , 3 . 85 ( m , 1H ) , 2 . 37 ( d , J (cid:1) 1 . 2 Hz , 3H ) , 2 . 03 ( m , 2H ) , 1 . 71 ( m , 2H ) , 1 . 48 – 1 . 27 ( m , 4H ) ; 13 C NMR ( MeOD , 100 MHz ) : δ 158 . 4 , 157 . 1 , 150 . 5 , 149 . 6 , 138 . 4 , 130 . 5 , 128 . 6 , 126 . 9 , 122 . 6 , 122 . 2 , 119 . 1 , 117 . 2 , 109 . 6 , 102 . 6 , 56 . 3 , 53 . 7 , 32 . 1 , 31 . 6 , 24 . 5 , 24 . 4 , 10 . 9 ; ESI - MS : [ M + H ] calc . 467 . 12 , found 467 . 30 . HR - MS ( ESI + ) : [ M + H ] calc . 467 . 1307 , found 467 . 1297 . 2 - Cyano - 1 - ( 3 - iodophenyl ) - 3 - ( ( 1 S , 2 S ) - 2 - ( ( 5 - methyl - 7 H - pyrrolo [ 2 , 3 - d ] pyrimidin - 4 - yl ) amino ) cyclohexyl ) guanidine ( 26 ) . Total yield : 11 % . Purity : > 99 % . mp : 128 – 129 ° C . 1 H NMR ( MeOD , 400 MHz ) : δ 7 . 74 ( s , 1H ) , 7 . 42 ( td , J (cid:1) 7 . 3 , 1 . 6 Hz , 1H ) , Frontiers in Chemistry | www . frontiersin . org December 2021 | Volume 9 | Article 781213 9 Ariawan et al . LIMK Selective Inhibitors 7 . 26 ( t , J (cid:1) 2 . 0 Hz , 1H ) , 6 . 88 – 6 . 79 ( m , 2H ) , 6 . 74 ( d , J (cid:1) 1 . 1 Hz , 1H ) , 4 . 03 ( m , 1H ) , 3 . 85 ( m , 1H ) , 2 . 37 ( d , J (cid:1) 1 . 2 Hz , 2H ) , 2 . 03 ( m , 2H ) , 1 . 71 ( m , 2H ) , 1 . 49 – 1 . 27 ( m , 4H ) ; 13 C NMR ( MeOD , 100 MHz ) : δ 158 . 5 , 157 . 1 , 150 . 4 , 149 . 7 , 138 . 2 , 134 . 7 , 132 . 9 , 130 . 5 , 123 . 3 , 119 . 1 , 117 . 2 , 109 . 6 , 102 . 6 , 93 . 5 , 56 . 2 , 53 . 8 , 32 . 1 , 31 . 6 , 24 . 5 , 24 . 4 , 10 . 9 ; ESI - MS : [ M + H ] calc . 515 . 11 , found 515 . 25 . HR - MS ( ESI + ) : [ M + H ] calc . 515 . 1169 , found 515 . 1157 . In Silico Docking Study The molecular docking study of all compounds was carried out in Schrodinger Glide Software package . The 2D structures of the newly synthetic compounds were accurately drawn using ChemDraw 19 . 0 software and then exported to Schrodinger Maestro . Crystal structures were prepared by downloading the pdf ﬁ le from the Protein Data Bank ( LIMK1 : 5NXC ; LIMK2 : 4TPT ) . Protein was prepared using protein preparation wizard within the Schrodinger package using default settings . Receptor grids are set up as 10 Å radius around the ATP binding pocket of LIMK . Inhibitors were docked into the receptor using the Glide SP method , and the pose with the lowest GLIDE binding score was selected for study . Schrodinger Maestro 12 . 7 was then used to visualise the interactions between the ligand molecules and LIMK . Biological Study LIMK1 ADP - Glo ™ Kinase Assay System ADP - Glo kinase assay was performed in 96 - well plate format using the Promega kinase assay system . LIMK1 ( 0 . 1 μ g ) and compounds ( 0 . 1 – 100 μ M ) were dissolved in kinase reaction buffer and incubated for 30 min at rt . The reaction was then initiated by the addition of ATP ( 10 μ M , 5 μ l ) and incubation for 30 min at 30 ° C . The reaction was then quenched with addition of 25 μ l of ADP - Glo reagent . Kinase detection reagent ( 50 μ l ) was added and incubated for 30 min prior to luminescence reading on the BMG Labtech PHERAstar FS plate reader . Kinase assay is performed as duplicate . 33 P - ATP Radiotracer Assay The radiotracer assay of LIMK1 and LIMK2 was performed by Reaction Biology Corporation . Compounds were tested in 10 - dose IC 50 mode with ﬁ vefold series dilution starting at 10 μ M . Reactions were carried out at 10 μ M 33 P - ATP , 1 μ M co ﬁ lin substrate , and 50 nM LIMK1 ( ﬁ nal concentration ) . Kinase activity is determined by the transfer or radioactive 33 P from ATP to co ﬁ lin substrate . Radiotracer assay is performed as triplicate . Scratch Assay The velocity of cell migration is measured using the C6 cell line in the 24 - well plate . Cells were seeded at 100 , 000 cells / well . After 24 h , cells were washed with warm PBS and treated with the inhibitors . Directly following the treatment , cells were moved into a preheated stage - top incubator maintained at 37 ° C / 5 % CO 2 , using the ZEISS Axio Observer live cell microscope , ﬁ tted with an Axiocam 702 mono camera . Cells were imaged once every 10 min using a × 10 objective with phase contrast for a 24 - h period . Cell migration was analysed using Fiji ImageJ ( NIH ) and Chemotaxis Migration Tool ( ibidi ) . DATA AVAILABILITY STATEMENT The original contributions presented in the study are included in the article / Supplementary Material , further inquiries can be directed to the corresponding author . AUTHOR CONTRIBUTIONS DA , LI , and MK designed the study . DA synthesised the compounds and performed the IC 50 testing . CA and EP performed the scratch assay . TF and YK supervised the experiments . YK , MK , and LI obtained the funding . DA , LI , and MK wrote the ﬁ rst draft of the manuscript . All authors reviewed and approved the manuscript . FUNDING This study was supported by the National Health and Medical Research Council ( 1123564 , 1136241 , 1132524 , 1143848 ) and Macquarie University . ACKNOWLEDGMENTS The authors acknowledge the Department of Molecular Sciences for access to NMR and melting point instrument . SUPPLEMENTARY MATERIAL The Supplementary Material for this article can be found online at : https : / / www . frontiersin . org / articles / 10 . 3389 / fchem . 2021 . 781213 / full # supplementary - material REFERENCES BenZablah , Y . , Merovitch , N . , Jia , Z . , andJia , Zhengping . ( 2020 ) . TheRoleofADF / Co ﬁ lin in Synaptic Physiology and Alzheimer ’ s Disease . Front . Cel Dev . Biol . 8 ( November ) , 1 – 20 . doi : 10 . 3389 / fcell . 2020 . 594998 Bernard , O . ( 2007 ) . LimKinases , RegulatorsofActinDynamics . Int . J . Biochem . Cel Biol . 39 ( 6 ) , 1071 – 1076 . doi : 10 . 1016 / j . biocel . 2006 . 11 . 011 Boland , S . , Bourin , A . , Alen , J . , Geraets , J . , Schroeders , P . , Castermans , K . , et al . ( 2015 ) . Design , Synthesis and Biological Characterization of Selective LIMK Inhibitors . Bioorg . Med . Chem . Lett . 25 ( 18 ) , 4005 – 4010 . doi : 10 . 1016 / j . bmcl . 2015 . 07 . 009 Bravo - Cordero , J . J . , Magalhaes , M . A . O . , Eddy , R . J . , Hodgson , L . , Condeelis , J . , Hodgson , Louis . , et al . ( 2013 ) . Functions of Co ﬁ lin in Cell Locomotion and Invasion . Nat . Rev . Mol . Cel Biol . 14 ( 7 ) , 405 – 415 . doi : 10 . 1038 / nrm3609 Frontiers in Chemistry | www . frontiersin . org December 2021 | Volume 9 | Article 781213 10 Ariawan et al . LIMK Selective Inhibitors Cui , J . , Ding , M . , Deng , W . , Yin , Y . , Wang , Z . , Zhou , H . , et al . ( 2015 ) . Discovery of Bis - Aryl Urea Derivatives as Potent and Selective Limk Inhibitors : Exploring Limk1 Activity and Limk1 / ROCK2 Selectivity through a Combined Computational Study . Bioorg . Med . Chem . 23 ( 23 ) , 7464 – 7477 . doi : 10 . 1016 / j . bmc . 2015 . 10 . 041 Davila , M . , Jhala , D . , Ghosh , D . , Grizzle , W . E . , and Chakrabarti , R . ( 2007 ) . Expression of LIM Kinase 1 Is Associated with Reversible G1 / S Phase Arrest , Chromosomal Instability and Prostate Cancer . Mol . Cancer 6 , 1 – 12 . doi : 10 . 1186 / 1476 - 4598 - 6 - 40 Goodwin , Nicole . C . , Cianchetta , Giovanni . , Burgoon , Hugh . A . , Healy , Jason . , Ross , Mabon . , Strobel , Eric . D . , et al . ( 2015 ) . Discovery of a Type III Inhibitor of LIM Kinase 2 that Binds in a DFG - Out Conformation . ACS Med . Chem . Lett . 6 ( 1 ) , 53 – 57 . doi : 10 . 1021 / ml500242y Harrison , B . A . , Whitlock , N . A . , Voronkov , M . V . , Almstead , Z . Y . , Gu , K . - j . , Mabon , R . , et al . ( 2009 ) . Novel Class of LIM - Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma . J . Med . Chem . 52 ( 21 ) , 6515 – 6518 . doi : 10 . 1021 / jm901226j Henderson , B . W . , Greathouse , K . M . , Ramdas , R . , Walker , C . K . , Rao , Tejeshwar . C . , Bach , Svitlana . V . , et al . ( 2019 ) . Pharmacologic Inhibition of LIMK1 Provides Dendritic Spine Resilience against β - amyloid . Sci . Signal . 12 ( 587 ) , eaaw9318 . doi : 10 . 1126 / scisignal . aaw9318 Heredia , L . , Helguera , P . , DeOlmos , S . , Kedikian , G . , Sola Vigo , F . , LaFerla , F . , etal . ( 2006 ) . Phosphorylation of Actin - Depolymerizing Factor / Co ﬁ lin by LIM - Kinase Mediates Amyloid - Induced Degeneration : A Potential Mechanism of Neuronal Dystrophy in Alzheimer ’ s Disease . J . Neurosci . 26 ( 24 ) , 6533 – 6542 . doi : 10 . 1523 / JNEUROSCI . 5567 - 05 . 2006 Kang , X . , Li , W . , Liu , W . , Liang , H . , Deng , J . , Wong , C . C . , et al . ( 2021 ) . LIMK1 Promotes Peritoneal Metastasis of Gastric Cancer and Is a Therapeutic Target . Oncogene 40 ( 19 ) , 3422 – 3433 . doi : 10 . 1038 / s41388 - 021 - 01656 - 1 Mathea , S . , Salah , E . , Pike , A . C . W . , Bushell , S . , Carpenter , E . P . , von Delft , F . , et al . ( 2017 ) . LIM Domain Kinase 1 ( LIMK1 ) in Complex with PF - 00477736LIM Domain Kinase ( LIMK1 ) in Complex with PF - 00477736 . doi : 10 . 2210 / pdb5NXC / pdb Murphy , M . P . , and Levine , H . ( 2010 ) . 19 , 311 – 323 . doi : 10 . 3233 / jad - 2010 - 1221Alzheimer ’ s Disease and the Amyloid - β Peptide J . Alzheimers Dis . Piccioli , Z . D . , and Littleton , J . T . ( 2014 ) . Retrograde BMP Signaling Modulates Rapid Activity - dependent Synaptic Growth via Presynaptic Lim Kinase Regulation of Co ﬁ lin . J . Neurosci . 34 ( 12 ) , 4371 – 4381 . doi : 10 . 1523 / JNEUROSCI . 4943 - 13 . 2014 Prunier , C . , Prudent , R . , Kapur , R . , Sadoul , K . , and Lafanechère , L . ( 2017 ) . LIM Kinases : Co ﬁ lin and beyond . Oncotarget 8 ( 25 ) , 41749 – 41763 . doi : 10 . 18632 / oncotarget . 16978 Rice , D . S . , Hansen , G . M . , Liu , F . , Crist , M . J . , Newhouse , M . M . , Potter , D . , et al . ( 2012 ) . KeratinocyteMigrationintheDevelopingEyelidRequiresLIMK2 . PLoS ONE 7 ( 10 ) , e47168 – 24 . doi : 10 . 1371 / journal . pone . 0047168 Rush , T . , Martinez - hernandez , J . , Dollmeyer , M . , Frandemiche , M . L . , Borel , E . , Boisseau , S . , et al . ( 2018 ) . Synaptotoxicity in Alzheimer ’ s Disease Involved a Dysregulation of Actin Cytoskeleton Dynamics through Co ﬁ lin 1 Phosphorylation . J . Neurosci . 38 ( 48 ) , 10349 – 10361 . doi : 10 . 1523 / jneurosci . 1409 - 18 . 2018 Scott , R . W . , and Olson , M . F . ( 2007 ) . LIM Kinases : Function , Regulation and Association with Human Disease . J . Mol . Med . 85 ( 6 ) , 555 – 568 . doi : 10 . 1007 / s00109 - 007 - 0165 - 6 Shi , W . , Ma , D . , Cao , Y . , Hu , L . , Liu , S . , Yan , D . , et al . ( 2021 ) . SphK2 / S1P Promotes Metastasis of Triple - Negative Breast Cancer through the PAK1 / LIMK1 / Co ﬁ lin1 Signaling Pathway . Front . Mol . Biosci . 8 ( April ) , 1 – 13 . doi : 10 . 3389 / fmolb . 2021 . 598218 Takahashi , H . , Koshimizu , U . , Miyazaki , J . - I . , and Nakamura , T . ( 2002 ) . Impaired Spermatogenic Ability of Testicular Germ Cells in Mice De ﬁ cient in the LIM - Kinase 2 Gene . Dev . Biol . 241 ( 2 ) , 259 – 272 . doi : 10 . 1006 / dbio . 2001 . 0512 Tanaka , K . , Takeda , S . , Mitsuoka , K . , Oda , T . , Kimura - Sakiyama , C . , Maéda , Y . , et al . ( 2018 ) . Structural Basis for Co ﬁ lin Binding and Actin Filament Disassembly . Nat . Commun . 9 ( 1 ) , 1 – 3 . doi : 10 . 1038 / s41467 - 018 - 04290 - w Vorster , P . J . , Guo , J . , Yoder , A . , Wang , W . , Zheng , Y . , Xu , X . , et al . ( 2011 ) . LIM Kinase 1 Modulates Cortical Actin and CXCR4 Cycling and Is Activated by HIV - 1 to Initiate Viral Infection . J . Biol . Chem . 286 ( 14 ) , 12554 – 12564 . doi : 10 . 1074 / jbc . M110 . 182238 Wen , X . , Ding , L . , Wang , J . - J . , Qi , M . , Hammonds , J . , Chu , H . , etal . ( 2014 ) . ROCK1 and LIM Kinase Modulate Retrovirus Particle Release and Cell - Cell Transmission Events . J . Virol . 88 ( 12 ) , 6906 – 6921 . doi : 10 . 1128 / jvi . 00023 - 14 Yi , F . , Guo , J . , Dabbagh , D . , Spear , M . , He , S . , Kehn - Hall , K . , etal . ( 2017 ) . Discovery of Novel Small - Molecule Inhibitors of LIM Domain Kinase for Inhibiting HIV - 1 . J . Virol . 91 ( 13 ) , e02418 – 16 . doi : 10 . 1128 / JVI . 02418 - 16 Yin , Y . , Zheng , K . , Eid , N . , Howard , S . , Jeong , J . - H . , Yi , F . , et al . ( 2015 ) . Bis - Aryl Urea Derivatives as Potent and Selective LIM Kinase ( Limk ) Inhibitors . J . Med . Chem . 58 ( 4 ) , 1846 – 1861 . doi : 10 . 1021 / jm501680m Yoshioka , K . , Foletta , V . , Bernard , O . , and Itoh , K . ( 2003 ) . ARoleforLIMKinasein Cancer Invasion . Proc . Natl . Acad . Sci . 100 ( 12 ) , 7247 – 7252 . doi : 10 . 1073 / pnas . 1232344100 Zhang , M . , Wang , R . , Tian , J . , Song , M . , Zhao , R . , Liu , K . , et al . ( 2021 ) . Targeting LIMK1 with Luteolin Inhibits the Growth of Lung Cancer In Vitro and In Vivo . J . Cel Mol Med 25 ( 12 ) , 5560 – 5571 . doi : 10 . 1111 / jcmm . 16568 Con ﬂ ict of Interest : The authors declare that the research was conducted in the absence of any commercial or ﬁ nancial relationships that could be construed as a potential con ﬂ ict of interest . Publisher ’ s Note : All claims expressed in this article are solely those of the authors and do not necessarily represent those of their af ﬁ liated organizations , or those of the publisher , the editors , and the reviewers . Any product that may be evaluated in this article , or claim that may be made by its manufacturer , is not guaranteed or endorsed by the publisher . Copyright © 2021 Ariawan , Au , Paric , Fath , Ke , Kassiou , van Eersel and Ittner . This is an open - access article distributed under the terms of the Creative Commons AttributionLicense ( CCBY ) . Theuse , distributionorreproductioninotherforumsis permitted , provided the original author ( s ) and the copyright owner ( s ) are credited and that the original publication in this journal is cited , in accordance with accepted academic practice . No use , distribution or reproduction is permitted which does not comply with these terms . Frontiers in Chemistry | www . frontiersin . org December 2021 | Volume 9 | Article 781213 11 Ariawan et al . LIMK Selective Inhibitors